THIRD AMENDMENT TO OEM AGREEMENT
Exhibit 10.4
*Confidential Treatment Requested Under
17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
THIRD AMENDMENT TO
OEM AGREEMENT
OEM AGREEMENT
This Third
Amendment to OEM Agreement, (“Amendment”) is made and
entered into as of October 26,
2005 (“Amendment Date”), by and between Akorn-Strides, LLC, a Delaware limited liability company,
having a principal place of business at 0000 Xxxxxxxxx Xxxxx, Xxxxxxx Xxxxx, Xxxxxxxx 00000-0000,
Xxxxxx Xxxxxx of America (“A-S”), and Strides Arcolab Limited, a company organized under the laws
of India having a principal place of business at Xxxxxxx Xxxxx, Xxxxxxxxxxx, Xxxxxxxxxxxx Xxxx,
Xxxxxxxxx 000 000, Xxxxx (“Strides”), (each a “Party” and collectively the “Parties”).
RECITALS
A. A-S and Strides are parties to that certain OEM Agreement dated September 22, 2004
(“Agreement”) and desire to amend the Agreement to revise the ANDA Schedule, pursuant to the terms
and conditions of this Amendment.
NOW, THEREFORE, in consideration of the mutual promises contained herein and other valuable
consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows:
1. Definitions. All capitalized terms used herein shall have the same meanings set forth
in the Agreement, unless otherwise defined in this Amendment.
2. Modification of ANDA Schedule. Exhibit B of the Agreement is deleted in its entirety
and replaced with Exhibit B attached hereto and fully incorporated herein (“New ANDA Schedule”).
The Parties also hereby acknowledge that the schedule, attached hereto as Attachment 1 was a
previously adopted, although unsigned schedule originally intended to supercede the original
Exhibit B attached to the Agreement but which itself is being superceded pursuant to this Amendment
with the New ANDA Schedule.
3. Counterparts. This Amendment may be executed in several counterparts that together
shall be originals and constitute one and the same instrument.
4. Effect. Except as modified above, the Agreement shall remain in full force and effect
in accordance with its specific terms.
IN WITNESS WHEREOF, the parties hereto, through their duly authorized officers, have executed this
Amendment as of the Amendment Date.
Akorn-Strides, LLC
|
Strides Arcolab Limited | ||||||
By:
|
/s/ Xxxxxx X. Xxxxxxx | By: | /s/ Xxxx Xxxxx | ||||
Name:
|
Xxxxxx X. Xxxxxxx | Name: | Xxxx Xxxxx | ||||
Its:
|
Member Manager | Its: | Executive Vice Chairman & MD | ||||
Page 1
*Confidential Treatment Requested Under
17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
EXHIBIT B
ANDA SCHEDULE
ANDA SCHEDULE
Dossier | API Cost | Upgrade | Total Cost of | Status of | ||||||||||
Sl. No. | Product Name | STRENGTH | Cost | over 10K | contbn | Dossier | Dossier | |||||||
1 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
2 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Semi- Exclusive** |
|||||||
3 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
4 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
5 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
6 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
7 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
8 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
9 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
10 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
11 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
12 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
13 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
14 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
15 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
[...*...] | [...*...] | [...*...] | [...*...] | |||||||||||
NOTE:-PRODUCTS CAN BE DROPPED OR SUBSTITUTED BASED ON JOINT DECISION BY AKORN/STRIDES JV |
** Notwithstanding the terms of this Agreement to the contrary, the Parties acknowledge that
[...*...] only may be sold by Strides in the Territory in the Exclusive Market to one other entity
only in addition to A-S.
* CONFIDENTIAL TREATMENT REQUESTED — This language has been omitted and filed
separately with the Securities and Exchange Commission.
*Confidential Treatment Requested under
17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
ATTACHMENT 1
SUPERCEDED INTERMEDIATE SCHEDULE
SUPERCEDED INTERMEDIATE SCHEDULE
Dossier | API Cost | Upgrade | Total Cost of | Status of | ||||||||||
Sl. No. | Product Name | STRENGTH | Cost | over 10K | contbn | Dossier | Dossier | |||||||
1 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
2 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Semi-Exclusive** | |||||||
3 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
4 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
5 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
6 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
7 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
8 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
9 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
10 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
11 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
12 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
13 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
14 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
15 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
16 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
17 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
18 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
19 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
20 | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | [...*...] | Exclusive | |||||||
[...*...] | [...*...] | [...*...] | [...*...] | |||||||||||
NOTE:-PRODUCTS CAN BE DROPPED OR SUBSTITUTED BASED ON JOINT DECISION BY AKORN/STRIDES JV |
* CONFIDENTIAL TREATMENT REQUESTED — This language has been omitted and filed
separately with the Securities and Exchange Commission.